Compare

P21 vs TB-500 Fragment

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

P21

1279 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 43% · Mixed 42% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
58
Appetite control
62
Energy
40
Mood
173
Focus
122

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
154
GI discomfort
142
Dizziness
185
Fatigue
168
Nausea
121

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.1–5 mg

0.1–0.2 mg
8
0.2–0.4 mg
17
0.4–0.6 mg
20
0.6–1 mg
30
1–2 mg
24
2–3 mg
18
3–5 mg
11

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing43stacking41side effects9p2112

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 35% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 281 repeat reporters

TB-500 Fragment

1497 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Focus
156
Sleep quality
30
Lean mass
59
Joint comfort
175
Recovery
122

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
72
Water retention
109
Appetite loss
24
Injection site reaction
171
Anxiety
121

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 200–400 mcg

Reports span 25–1000 mcg

25–50
2
50–100
5
100–200
10
200–400
20
400–600
15
600–1000
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17tb-500 fragment30

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 329 repeat reporters

Sources (5)

Published sources linked on the P21 and TB-500 Fragment wiki pages.

  1. PubMed

    Ciliary neurotrophic factor (CNTF) and related peptides in neuroprotection

    Peterson WM, Wang Q, Tzekova R, et al. Prog Retin Eye Res. 2013

    Source
    Wiki study page →
  2. PubMed

    The effect of exogenous ciliary neurotrophic factor on cell cycle and neural differentiation markers of in vitro model cells: New insights for future therapeutic approaches

    Ghasemi M, Alizadeh E, Motlagh BF, et al. Cell biochemistry and function. 2021

    Source
    Wiki study page →
  3. PubMed

    Thymosin beta4: a multi-functional regenerative peptide (review)

    Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  4. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  5. PubMed

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026

    Source
    Wiki study page →